Dr. Wouter Latour Joins PharmaJet as Chief Executive Officer [Yahoo! Finance]
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
GOLDEN, Colo., October 02, 2024 BUSINESS WIRE PharmaJet ® , a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that Wouter Latour, M.D., has joined the company as Chief Executive Officer (CEO). Latour also joins the PharmaJet board of directors. He succeeds Chris Cappello who has recently been elected Vice-Chairman of the Board and will remain active in the business, largely focused on strategic partners and supporting engineering/operations. Dr. Latour brings more than 30 years of industry experience to PharmaJet, most recently as CEO, President and Director, and Chairman of the Board at Vaxart, Inc., a clinical stage biotechnology company developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. At Vaxart, he took the company public, and advanced a pipeline of oral vaccine candidates targeting COVID 19, flu, norovirus, RSV and HPV. Previous roles included CEO and Director
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate [Yahoo! Finance]Yahoo! Finance
- Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateGlobeNewswire
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13GlobeNewswire
VXRT
Earnings
- 11/13/24 - Beat
VXRT
Sec Filings
- 12/17/24 - Form 4
- 12/5/24 - Form 8-K
- 11/13/24 - Form 10-Q
- VXRT's page on the SEC website